Journal of the Formosan Medical Association,
Год журнала:
2023,
Номер
123(1), С. 88 - 97
Опубликована: Июнь 20, 2023
Coronavirus
disease
2019
(COVID-19)
vaccines
were
rapidly
implemented
globally
and
vaccine-associated
immune-related
hepatitis
was
recently
reported.
We
aim
to
investigate
its
impact
in
regions
endemic
of
chronic
B
(CHB).
Journal of Medical Virology,
Год журнала:
2024,
Номер
96(7)
Опубликована: Июль 1, 2024
Abstract
Although
previous
studies
have
focused
on
hepatobiliary
and
gastrointestinal
adverse
drug
reactions
(ADRs)
associated
with
COVID‐19
vaccines,
literature
such
ADRs
other
vaccines
is
limited,
particularly
a
global
scale.
Therefore,
we
aimed
to
investigate
the
burden
of
vaccine‐associated
identify
implicated
in
these
occurrences.
This
study
utilized
data
from
World
Health
Organization
(WHO)
international
pharmacovigilance
database
extract
reports
1967
2023
(total
=
131
255
418).
Through
reporting
counts,
reported
odds
ratios
(ROR)
95%
confidence
interval
(CI),
information
components
(IC)
IC
0.25
,
examined
association
between
16
incidence
across
156
countries.
Of
6
842
303
ADRs,
10
786
liver
injury,
927
870
symptoms,
2978
pancreas
bile
duct
96
intra‐abdominal
hemorrhage
were
identified.
Most
surged
after
2020,
majority
attributed
messenger
RNA
(mRNA)
vaccines.
Hepatitis
A
exhibited
highest
injury
(ROR
[95%
CI]:
10.30
[9.65–10.99];
[IC
]:
3.33
[3.22]),
followed
by
hepatitis
B,
typhoid,
rotavirus.
Specifically,
ischemic
had
significant
both
Ad5‐vectored
mRNA
Gastrointestinal
symptoms
all
except
for
tuberculosis
rotavirus
(11.62
[11.45–11.80];
3.05
[3.03])
typhoid
(11.02
[10.66–11.39];
3.00
[2.96]).
Pancreas
(1.99
[1.89–2.09];
0.90
[0.83]),
MMR
(measles,
mumps,
rubella),
papillomavirus
For
hemorrhage,
inactivated
whole‐virus
(3.93
[1.86–8.27];
1.71
[0.41])
association,
(1.81
[1.42–2.29];
0.77
[0.39]).
short
time
onset,
within
1
day,
low
mortality
rate.
scale
database,
occurred
emphasizing
importance
healthcare
workers'
vigilant
monitoring
timely
management.
PLoS Medicine,
Год журнала:
2023,
Номер
20(7), С. e1004274 - e1004274
Опубликована: Июль 24, 2023
Background
The
risk
of
incident
diabetes
following
Coronavirus
Disease
2019
(COVID-19)
vaccination
remains
to
be
elucidated.
Also,
it
is
unclear
whether
the
after
Severe
Acute
Respiratory
Syndrome
2
(SARS-CoV-2)
infection
modified
by
status
or
differs
SARS-CoV-2
variants.
We
evaluated
incidence
mRNA
(BNT162b2),
inactivated
(CoronaVac)
COVID-19
vaccines,
and
infection.
Methods
findings
In
this
population-based
cohort
study,
individuals
without
known
were
identified
from
an
electronic
health
database
in
Hong
Kong.
first
included
people
who
received
≥1
dose
vaccine
those
did
not
receive
any
vaccines
up
September
2021.
second
consisted
confirmed
patients
never
infected
March
2022.
Both
cohorts
followed
until
August
15,
A
total
325,715
recipients
(CoronaVac:
167,337;
BNT162b2:
158,378)
145,199
1:1
matched
their
respective
controls
using
propensity
score
for
various
baseline
characteristics.
also
adjusted
previous
when
estimating
conditional
probability
receiving
vaccinations,
contracting
Hazard
ratios
(HRs)
95%
confidence
intervals
(CIs)
estimated
Cox
regression
models.
cohort,
we
5,760
4,411
cases
CoronaVac
BNT162b2
respectively.
Upon
a
median
follow-up
384
386
days,
there
was
no
evidence
increased
risks
9.08
versus
9.10
per
100,000
person-days,
HR
=
0.998
[95%
CI
0.962
1.035];
7.41
8.58,
0.862
[0.828
0.897]),
regardless
type.
observed
2,109
164
associated
with
significantly
higher
(9.04
7.38,
1.225
[1.150
1.305])—mainly
type
diabetes—regardless
predominant
circulating
variants,
albeit
lower
Omicron
variants
(p
interaction
0.009).
number
needed
harm
at
6
months
406
1
additional
case.
Subgroup
analysis
revealed
among
fully
vaccinated
survivors.
Main
limitations
our
study
possible
misclassification
bias
as
through
diagnostic
coding
residual
confounders
due
its
observational
nature.
Conclusions
There
vaccination.
infection,
mainly
diabetes.
excess
lower,
but
still
statistically
significant,
Fully
might
protected
Nano-Micro Letters,
Год журнала:
2025,
Номер
17(1)
Опубликована: Фев. 21, 2025
The
emerging
messenger
RNA
(mRNA)
nanomedicines
have
sprung
up
for
disease
treatment.
Developing
targeted
mRNA
has
become
a
thrilling
research
hotspot
in
recent
years,
as
they
can
be
precisely
delivered
to
specific
organs
or
tissues
enhance
efficiency
and
avoid
side
effects.
Herein,
we
give
comprehensive
review
on
the
latest
progress
of
with
targeting
functions.
its
carriers
are
first
described
detail.
Then,
mechanisms
passive
targeting,
endogenous
active
outlined,
focus
various
biological
barriers
that
may
encounter
during
vivo
delivery.
Next,
emphasis
is
placed
summarizing
mRNA-based
organ-targeting
strategies.
Lastly,
advantages
challenges
clinical
translation
mentioned.
This
expected
inspire
researchers
this
field
drive
further
development
technology.
Gut,
Год журнала:
2023,
Номер
72(9), С. 1783 - 1794
Опубликована: Июнь 14, 2023
SARS-CoV-2
infection
may
affect
the
liver
in
healthy
individuals
but
also
influences
course
of
COVID-19
patients
with
chronic
disease
(CLD).
As
described
individuals,
a
strong
SARS-CoV-2-specific
adaptive
immune
response
is
important
for
outcome
COVID-19,
however,
knowledge
on
CLD
limited.Here,
we
review
clinical
and
immunological
features
CLD.
Acute
injury
occurs
many
cases
be
induced
by
multiple
factors,
such
as
cytokines,
direct
viral
or
toxic
effects
drugs.
In
CLD,
have
more
severe
promote
decompensation
particularly
cirrhosis.
Compared
responses
impaired
after
both,
natural
vaccination
improves
at
least
partially
booster
vaccination.Following
vaccination,
rare
acute
vaccine-induced
development
autoimmune-like
hepatitis
been
reported.
However,
concomitant
elevation
enzymes
reversible
under
steroid
treatment.
Journal of Hepatology,
Год журнала:
2023,
Номер
79(3), С. 666 - 676
Опубликована: Июнь 7, 2023
Liver
injury
after
COVID-19
vaccination
is
very
rare
and
shows
clinical
histomorphological
similarities
with
autoimmune
hepatitis
(AIH).
Little
known
about
the
pathophysiology
of
vaccine-induced
liver
(VILI)
its
relationship
to
AIH.
Therefore,
we
compared
VILI
AIH.Formalin-fixed
paraffin-embedded
biopsy
samples
from
patients
(n
=
6)
an
initial
diagnosis
AIH
9)
were
included.
Both
cohorts
by
evaluation,
whole-transcriptome
spatial
transcriptome
sequencing,
multiplex
immunofluorescence,
immune
repertoire
sequencing.Histomorphology
was
similar
in
both
but
showed
more
pronounced
centrilobular
necrosis
VILI.
Gene
expression
profiling
that
mitochondrial
metabolism
oxidative
stress-related
pathways
interferon
response
less
enriched
Multiplex
analysis
revealed
inflammation
dominated
CD8+
effector
T
cells,
drug-induced
autoimmune-like
hepatitis.
In
contrast,
a
dominance
CD4+
cells
CD79a+
B
plasma
cells.
T-cell
receptor
(TCR)
B-cell
sequencing
cell
clones
dominant
than
addition,
many
detected
also
found
blood.
Interestingly,
TCR
beta
chain
Ig
heavy
variable-joining
gene
usage
further
TRBV6-1,
TRBV5-1,
TRBV7-6,
IgHV1-24
genes
are
used
differently
AIH.Our
analyses
support
SARS-CoV-2
related
distinct
differences
histomorphology,
pathway
activation,
cellular
infiltrates,
usage.
may
be
separate
entity,
which
closely
hepatitis.Little
(VILI).
Our
shares
some
hepatitis,
has
such
as
increased
activation
metabolic
pathways,
prominent
infiltrate,
oligoclonal
response.
findings
suggest
disease
entity.
there
good
chance
will
recover
completely
not
develop
long-term
Abstract
Background
In
view
of
accumulating
case
reports
thyroid
dysfunction
following
COVID-19
vaccination,
we
evaluated
the
risks
incident
inactivated
(CoronaVac)
and
mRNA
(BNT162b2)
vaccines
using
a
population-based
dataset.
Methods
We
identified
people
who
received
vaccination
between
23
February
30
September
2021
from
electronic
health
database
in
Hong
Kong,
linked
to
records.
Thyroid
encompassed
anti-thyroid
drug
(ATD)/levothyroxine
(LT4)
initiation,
biochemical
picture
hyperthyroidism/hypothyroidism,
Graves’
disease
(GD),
thyroiditis.
A
self-controlled
series
design
was
used
estimate
incidence
rate
ratio
(IRR)
56-day
post-vaccination
period
compared
baseline
(non-exposure
period)
conditional
Poisson
regression.
Results
total
2,288,239
at
least
one
dose
(57.8%
BNT162b2
recipients
42.2%
CoronaVac
recipients).
94.3%
92.2%
second
dose.
Following
first
there
no
increase
ATD
initiation
(BNT162b2:
IRR
0.864,
95%
CI
0.670–1.114;
CoronaVac:
0.707,
0.549–0.912),
LT4
0.911,
0.716–1.159;
0.778,
0.618–0.981),
hyperthyroidism
0.872,
0.744–1.023;
0.830,
0.713–0.967)
or
hypothyroidism
1.002,
0.838–1.199;
0.963,
0.807–1.149),
GD,
Similarly,
0.972,
0.770–1.227;
0.879,
95%CI
0.693–1.116),
1.019,
0.833–1.246;
0.768,
0.613–0.962),
1.039,
0.899–1.201;
0.786–1.055),
0.935,
0.794–1.102;
0.945,
0.799–1.119),
Age-
sex-specific
subgroup
sensitivity
analyses
showed
consistent
neutral
associations
both
types
vaccines.
Conclusions
Our
study
evidence
vaccine-related
with
CoronaVac.
Viruses,
Год журнала:
2022,
Номер
14(12), С. 2778 - 2778
Опубликована: Дек. 13, 2022
Vaccination
against
SARS-CoV-2
has
become
a
central
public
health
issue,
primarily
for
vulnerable
populations
such
as
individuals
with
Chronic
Liver
Disease
(CLD).
Increased
COVID-19-related
mortality
and
disease
severity
been
noted
in
this
subgroup
of
patients.
Severe
COVID-19
tends
to
further
deregulate
liver
function
patients
chronic
failure
or
cirrhosis
even
reactivate
hepatitis
people
living
HBV
HCV.
In
addition,
impaired
hepatic
leads
several
limitations
possible
therapeutic
interventions.
dysregulation,
along
the
underlying
cirrhosis-associated
immune
dysfunction
(CAID),
decreased
response
vaccination
that,
turn,
may
result
reduced
efficacy
rates
lowered
lasting
protection.
According
current
guidelines,
timely
frequent
booster
shot
administration
are
deemed
necessary
context.
Vaccination-related
adverse
events
mostly
mild
nature
similar
those
reported
general
population,
whereas
incidence
injury
following
is
relatively
rare.
We
aimed
review
available
evidence
recommendations
associated
disease,
provide
insight
issues
future
directions.
Emerging Microbes & Infections,
Год журнала:
2023,
Номер
12(1)
Опубликована: Март 5, 2023
Severe
COVID-19
appears
to
be
disproportionately
more
common
in
children
and
adolescents
since
the
emergence
of
Omicron.
More
evidence
regarding
vaccine
effectiveness
(VE)
is
urgently
needed
assist
policymakers
making
decisions
minimize
hesitancy
among
public.
This
was
a
case-control
study
pediatric
population
using
data
extracted
from
electronic
health
records
database
Hong
Kong.
Individuals
aged
3-17
with
confirmed
by
polymerase
chain
reaction
were
included
study.
Each
case
matched
up
10
controls
based
on
age,
gender,
index
date
(within
3
calendar
days).
The
VE
BNT162b2
CoronaVac
preventing
COVID-19,
hospitalizations,
severe
outcomes
estimated
conditional
logistic
regression
adjusted
patients'
comorbidities
medication
history
during
outbreak
January
August
2022.
A
total
36,434
cases,
2231
COVID-19-related
1918
cases
109,004,
21,788,
18,823
controls,
respectively.
Compared
unvaccinated
group,
three
doses
or
associated
reduced
risk
infection
[VE:
BNT162b2:
56.0%
(95%
CI:
49.6-61.6),
CoronaVac:
39.4%
25.6-50.6)],
hospitalization
58.9%
36.1-73.6),
51.7%
(11.6-73.6)],
60.2%
33.7-76.1),
42.2%
-6.2-68.6)].
Our
findings
showed
that
effective
Omicron-dominant
pandemic,
which
further
enhanced
after
booster
dose.